	US 12,201,096 B2
	Non-human animals comprising a humanized coagulation factor 12 locus
Yajun Tang, White Plains, NY (US); Dan Chalothorn, New York, NY (US); Lyndon Mitnaul, Piscataway, NJ (US); Lori Morton, Chappaqua, NY (US); Daria Zamolodchikov, Hastings-on-Hudson, NY (US); Nicole Alessandri-Haber, Rye Brook, NY (US); and Lynn Macdonald, Harrison, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jul. 5, 2023, as Appl. No. 18/347,009.
Application 18/347,009 is a division of application No. 16/838,519, filed on Apr. 2, 2020, granted, now 11,737,435.
Claims priority of provisional application 62/829,321, filed on Apr. 4, 2019.
Prior Publication US 2024/0016129 A1, Jan. 18, 2024
Int. Cl. A01K 67/0278 (2024.01); C07K 14/745 (2006.01); C12N 9/22 (2006.01); C12N 15/86 (2006.01); C12Q 1/6876 (2018.01)

CPC A01K 67/0278 (2013.01) [C07K 14/745 (2013.01); C12N 9/22 (2013.01); C12N 15/86 (2013.01); C12Q 1/6876 (2013.01); A01K 2207/15 (2013.01); A01K 2217/072 (2013.01); A01K 2217/203 (2013.01); C12N 2310/20 (2017.05)]

16 Claims

1. A method of assessing expression of a short F12 mRNA isoform in a biological sample, comprising:

(a) detecting and quantifying RNA transcripts using primers and/or probes against one or more of exons 9-14 of an F12 gene; and

(b) detecting and quantifying RNA transcripts using primers and/or probes against one or more of exons 1-6 of the F12 gene

wherein the short isoform is detected by primers and/or probes against exons 9-14 but not by primers and/or probes against exons 1-6.